Board discusses enforcement factors for cost‑growth targets; debate centers on high‑cost drugs

The Office of Health Care Affordability asked the board to advise which factors should be considered when entities exceed the state's spending growth targets, with particular attention to whether high‑cost drugs should justify limited or broad relief. Staff summarized the statute’s enforcement considerations — including an entity’s contribution to excess cost growth, actions that erode access or quality, controllability of cost drivers and whether circumstances fall outside the entity’s control. The statute also permits a waiver for “reasonable factors outside the entity’s control,” such as changes in state or federal law, or extraordinary events. Why this matters: the office must weigh systemic pressures (for example, new expensive…